Patents
Literature
57 results about "Immunodeficiency" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunodeficiency is a state in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. Most cases of immunodeficiency are acquired ("secondary") due to extrinsic factors that affect the patient's immune system. Examples of these extrinsic factors include HIV infection, extremes of age, and environmental factors, such as nutrition. In the clinical setting, the immunosuppression by some drugs, such as steroids, can be either an adverse effect or the intended purpose of the treatment. Examples of such use is in organ transplant surgery as an anti-rejection measure and in patients suffering from an overactive immune system, as in autoimmune diseases. Some people are born with intrinsic defects in their immune system, or primary immunodeficiency. A person who has an immunodeficiency of any kind is said to be immunocompromised. An immunocompromised person may be particularly vulnerable to opportunistic infections, in addition to normal infections that could affect everyone. Immunodeficiency also decreases cancer immunosurveillance, in which the immune system scans the body's cells and kills neoplastic ones.
Application of vitamin K3 in preparation of medicine for treating psoriasis
PendingCN121401245AOrganic active ingredientsDermatological disorderAntiendomysial antibodiesVitamin K3
The invention belongs to the technical field of biological medicines, and discloses application of vitamin K3 in preparation of a medicine for treating psoriasis. The invention finds that the compound vitamin K3 can obviously inhibit the activation of the STING downstream immune pathway and has an inhibition effect on the activation of the STING pathway. A mouse psoriasis model is formulated according to the absorption and metabolism characteristics of the inhibitor VK3, and it is proved that the VK3 can significantly inhibit the process of psoriasis and up-regulation of an STING pathway at an affected part in a transdermal drug delivery mode. The STING pathway does not belong to a main pathway affecting the course of disease in most non-immunodeficient inflammatory diseases, so that a better treatment effect may be generated by using the STING pathway in combination with a direct treatment drug (such as an IL-17A antibody for psoriasis). The vitamin K3 is simple in chemical structure, mature in production process and low in preparation cost, has more remarkable price advantage compared with biological agents and small-molecule targeting drugs, and has high popularization value and application prospects.
Owner:SUN YAT SEN UNIV
Colu virus attenuated strain and application thereof
PendingCN121628844ASsRNA viruses negative-senseViral antigen ingredientsImmunodeficiencyHumoral immune reaction
The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Drug conjugates of imidazo quinoline amine derivatives, compositions and methods thereof
The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).
Owner:CANWELL BIOTECH LTD
Anti-CD28 antibodies and uses thereof
The invention relates to an anti-CD28 antibody or an antigen binding fragment thereof, and a multispecific antibody constructed based on the antibody or the antigen binding fragment thereof, such as an anti-CD3 * CD28 bispecific antibody and an anti-tumor associated antigen (TAA) * CD3 * CD28 trispecific antibody. The invention also relates to a nucleic acid molecule encoding the antibody or the antigen binding fragment thereof, a vector and a cell comprising the nucleic acid molecule, a pharmaceutical composition comprising the antibody or the antigen binding fragment thereof, and application of the antibody or the antigen binding fragment thereof, especially application of the antibody or the antigen binding fragment thereof in treating tumors or immunodeficiency diseases.
Owner:CYTOCARES (SHANGHAI) INC
Cpg oligodeoxynucleotide with regulating body immune capacity and its application
ActiveCN118909014BOrganic active ingredientsAntibacterial agentsImmunodeficiencyImmune dysregulation
The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.
Owner:NANJING JSIAMA BIOPHARMACEUTICALS LTD
Hemoglobin-related gene for diagnosing immune status and use thereof
PCT designated stageWO2026005512A1Microbiological testing/measurementBiological testingImmunodeficiencyRelated gene
The present invention relates to a composition for diagnosing immunodeficiency or a method for providing information for diagnosis thereof. By using the composition and the method according to one aspect, it is possible to simply and effectively diagnose immune-deficient conditions such as immunosuppression or immune paralysis.
Owner:SUNG KWANG MEDICAL FOUND
AAVR knockout mouse in combination with human liver chimerism and methods of use and production of the same
PendingUS20260007122A1Compounds screening/testingCell receptors/surface-antigens/surface-determinantsImmune compromisedKnockout animal
The present disclosure provides an immunodeficient or immune-impaired chimeric non-human animal with a deletion or impairment of adeno-associated virus receptor (AAVR), comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to evaluate transduction efficiency of adeno-associated viruses (AAV), and determine mechanism of inhibition / modification of AAV transduction in human hepatocytes.
Owner:AVACHROME INC
Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
PendingJP2026010043AInorganic boron active ingredientsEnergy modified materialsNeutron captureImmunodeficiency
To provide new and improved methods of treating cancer, immune disorders, and other diseases utilizing borylated amino acids and neutron capture therapy (NCT).SOLUTION: Disclosed herein are borylated amino acid ("BAA") compositions and methods of making BAAs. Accordingly, BAAs can be administered to patients as neutron capture agents and can provide methods of treating cancer, immune disorders, and other diseases by utilizing neutron capture therapy modalities. The invention described herein relates to the field of boron neutron capture therapy (BNCT). In particular, the present invention relates to borylated amino acid ("BAA") or ("BAAs") compositions that can be used as a vehicle for neutron capture therapy in humans. The invention further relates to the treatment of cancer and other immune disorders and diseases.SELECTED DRAWING: None
Owner:TAE LIFE SCIENCES LLC
Non-human autoimmune disease model animal, myositis model animal, method for producing same, and use thereof
PCT designated stageWO2025258683A1Microbiological testing/measurementBlood/immune system cellsImmunologic disordersPeripheral blood mononuclear cell
Provided is a non-human autoimmune disease model animal derived from an immunodeficient non-human animal as a pathologic model animal in which symptoms of an autoimmune disease are more faithfully reproduced, wherein peripheral blood mononuclear cells (PBMCs) derived from a heterologous animal subjected to CD8-positive T cell removal treatment are transfected, and symptoms of an autoimmune disease are exhibited.
Owner:TANABE PHARMA CORP
Novel latilactobacillus curvatus strain having immunoenhancing efficacy and immunoenhancing composition comprising same
PCT designated stageWO2026075443A1BacteriaAnimal feeding stuffPhosphorylationNatural Killer Cell Inhibitory Receptors
The present invention relates to a novel Latilactobacillus curvatus strain WiKim0169 having immunoenhancing efficacy, and an immunoenhancing composition comprising same. In the present invention, it was found that the Latilactobacillus curvatus strain WiKim0169, which is a novel kimchi-derived strain, significantly increases splenic NK cell activity and increases the production of inflammatory mediators, immunoglobulins, and cytokines, thereby alleviating immunosuppressive responses. In addition, it was confirmed that the Latilactobacillus curvatus strain WiKim0169 has an effect of alleviating immune dysfunction by increasing the mRNA expression levels of iNOS, COX2, TNF-α, IL-1β, IL-6, IL-2, IL-12, and IL-10 in splenic tissue and increasing the phosphorylation levels of NF-κB and IκBα. Therefore, according to the present invention, the composition comprising the Latilactobacillus curvatus strain WiKim0169, which is a novel kimchi-derived strain, as an active ingredient is expected to be usefully employed as a pharmaceutical and functional food composition for immunoenhancement.
Owner:PHARMSVILLE
Tgfbeta signal convertor
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Owner:REGENERON PHARMACEUTICALS INC
Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating myelodysplastic syndrome
The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating myelodysplastic syndrome and related complications thereof. The traditional Chinese medicine composition comprises sculellaria barbata, astragalus membranaceus, angelica sinensis, nightshade, radix curcumae, red ginseng, duchesnea indica, saussurea involucrata, cyclea verticillata and salvia miltiorrhiza. The traditional Chinese medicine composition has a good prevention and treatment effect on myelodysplastic syndrome and related complications thereof, can effectively inhibit proliferation of hematological tumor cells, and also can inhibit proliferation of the myelodysplastic syndrome by increasing the hemoglobin level, reducing the inflammatory cytokine level and reducing the proportion of peripheral blood T cells. Anemia, inflammation and low immune function caused by the myelodysplastic syndrome can be treated. The invention provides an effective strategy for prevention or treatment of myelodysplastic syndrome and related complications thereof, and provides a new direction for application of the traditional Chinese medicine composition.
Owner:GUIYANG XINTIAN PHARMA CO LTD +1
Application of Lactobacillus rhamnosus fermented ginseng freeze-dried powder in the preparation of immunomodulatory drugs
This invention discloses the application of *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder in the preparation of immunomodulatory drugs, belonging to the field of bio-fermentation and immunomodulation technology. The *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder is prepared by fermenting ginseng with *Lactobacillus rhamnosus*. The rare ginsenosides include at least one of Ck, Rk1, Rh4, and Rg5. The immunomodulatory drug is used to improve cyclophosphamide-induced immunodeficiency. The amount of *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder added to the immunomodulatory drug is 10%-50% (mass fraction). The preparation method of the *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder is as follows: S1, ginseng pretreatment; S2, strain activation; S3, fermentation culture; S4, freeze-dried powder preparation. This invention has the technical effects of high bioavailability of ginseng active ingredients, significant immunomodulatory effect, good safety, and effective improvement of cyclophosphamide-induced immunodeficiency.
Owner:JILIN AGRI SCI & TECH COLLEGE
Camptothecin analogs, conjugates, and methods of use
Camptothecin analogs of formula (I), (II), (III) are described, as well as conjugates comprising these camptothecin analogs. These camptothecin analogs and conjugates are useful as therapeutic agents, particularly for the treatment of cancer, infectious diseases, inflammatory diseases, autoimmune diseases, and immunodeficiency diseases.
Owner:NONA BIOSCIENCES (SUZHOU) CO LTD
CD33 targeted immunotherapies
The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Owner:REGENERON PHARMACEUTICALS INC +1
2-amino-4-methylquinazoline compounds, processes for their preparation, uses and pharmaceutical compositions
This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Dosage forms for local injection containing eltrombopag for use in treating degenerative diseases and improving stem cell homing - Patent Application 20070122999
PendingJP2025542310APowder deliveryOrganic active ingredientsImmunologic disordersAutoimmune condition
The present invention relates to a controlled-release pharmaceutical composition comprising at least a controlled-release pharmaceutical dosage form containing EPAG, the controlled-release pharmaceutical composition being suitable for local injection into an affected area. The present invention also relates to a controlled-release pharmaceutical composition in powder form for preparing the pharmaceutical composition suitable for local injection, and a kit for preparing the pharmaceutical composition comprising an aqueous injection vehicle and a controlled-release dosage form or a mixture of controlled and immediate-release dosage forms containing EPAG, the pharmaceutical composition optionally including an excipient. The composition is useful for local injection in patients to improve stem cell homing and / or treat non-malignant hematological disorders, malignant hematological diseases, primary immunodeficiencies, autoimmune diseases, inborn errors of metabolism, and / or degenerative diseases / injuries.
Owner:PK MED SAS
Embryo-like model and construction method and application thereof
The invention provides a construction method of an embryo-like model, which comprises the following steps: culturing primitive state stem cells in vitro or injecting the primitive state stem cells into an immunodeficient animal body for differentiation to obtain the embryo-like model. According to the method, in the process of preparing the embryo-like model, cell factors and small molecular pathway interference factors do not need to be added, gene editing is not needed, only a single starting cell type is adopted, and the method has the advantages of being simple and high in repeatability, facilitates large-scale preparation and application, and has wide application prospects. And the prepared embryo-like model has all embryo external cell lineages and all embryo internal cell lineages except for trophoderm, and can simulate the development process from an implanted embryo of a Carbonate-resistant group 3 stage to a Carbonate-resistant group 9 stage nerve embryo, so that the embryo-like model can be used for preparing various progenitor cell lineages, modeling diseases, screening drugs and carrying out scientific research.
Owner:SHENZHEN HUADA GENE INST +1
A boletus xylan palmitate, a preparation method and application thereof
The application discloses a brown ring lactarius xylolipalm and a preparation method and application thereof. The brown ring lactarius xylolipalm is xylolipalm formed by taking alpha-(1→4)-xylose as a main chain, alpha-(1→)-glucose as a branch chain and a palmitic acid molecule through an ester bond. The application further discloses a preparation method of the brown ring lactarius xylolipalm and an application thereof in immune regulation, and the brown ring lactarius xylolipalm can be used as a dietary supplement or a food additive for immunodeficiency patients or tumor patients.
Owner:YANTAI UNIV
Engineered T cells
ActiveUS12590136B2Peptide/protein ingredientsVirus peptidesAdoptive cellular therapyImmunologic disorders
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Owner:MEDIGENE IMMUNOTHERAPIES GMBH +1
Irak4 degrader and uses thereof
This invention relates to an IRAK4 degrading agent and its uses. This degrading agent can be used to treat or prevent diseases such as cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, cell death-related conditions, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases, or CNS diseases.
Owner:BEIJING SHUANGHE RUNCHUANG TECH CO LTD
A composition for preventing and improving sarcopenia, immunodeficiency caused by cancer and related treatments, and a preparation method and application thereof
The application belongs to the technical field of biological medicine, and provides a composition for preventing and improving cancer and sarcopenia caused by related treatment and immunodeficiency, a preparation method and application thereof.The composition comprises the following components: nucleotides, beta-hydroxy beta-methyl butyrate, arginine, histidine, glutathione, fish oil, seaweed oil and vitamin E.The composition has remarkable effects on improving cancer and sarcopenia caused by related treatment and immunodeficiency in the compounding of the components.
Owner:THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
CD33 targeted immunotherapies
PendingUS20260132184A1VirusesPeptide/protein ingredientsAdoptive cellular therapyImmunologic disorders
The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Owner:REGENERON PHARMACEUTICALS INC +1
Novel pediococcus acidilactici strain having immunity-enhancing efficacy and composition for enhancing immunity, comprising same
The present invention relates to a novel Pediococcus acidilactici WiKim0170 strain having immunity-enhancing efficacy and a composition for enhancing immunity, comprising same. In the present invention, it has been discovered that the Pediococcus acidilactici WiKim0170 strain, which is a novel strain derived from makgeolli, significantly increases spleen NK cell activity and increases inflammatory mediator, immunoglobulin, and cytokine production amounts, thereby improving an immunosuppressive reaction. In addition, the Pediococcus acidilactici WiKim0170 strain has been confirmed to increase the mRNA expression levels of iNOS, COX2, TNF-α, IL-1β, IL-6, IL-2, IL-12, and IL-10 in spleen tissue and increase the phosphorylation levels of NF-κB and IκBα, thereby having an effect of mitigating decreased immunity. Thus, according to the present invention, the composition comprising the Pediococcus acidilactici WiKim0170 strain, which is a novel strain derived from makgeolli, as an active ingredient is expected to be usefully employable as a pharmaceutical and functional food composition for enhancing immunity.
Owner:PHARMSVILLE
Targeted protein degradation compound as well as preparation method and application thereof
PendingCN120981450AOrganic active ingredientsOrganic chemistryAutoimmune conditionImmunodeficiency disease
The invention relates to a targeted protein degradation compound as well as a preparation method and application thereof, and belongs to the field of medicines. Specifically, the invention relates to a compound as shown in a general formula (I), a preparation method thereof and a pharmaceutical composition containing the compound, the invention also relates to the application of the compound in preparation of medicines for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplantation-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases and the like. The invention also relates to the application of the medicine for treating diseases related to cell death or cardiovascular diseases. Wherein each substituent in the general formula (I) is as defined in the specification. B-L-K (I)
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD
Method for screening non-tumorigenic mdck monoclonal strains, cell strains, applications and cell banks
This invention discloses a screening method, cell line, application, and cell bank for non-tumorigenic MDCK monoclonal strains, belonging to the field of biotechnology. The screening method includes: serum-free acclimation culture of a heterogeneous MDCK cell population; monoclonal isolation of the acclimated cell population to obtain candidate monoclonal cell lines; tumorigenicity screening by inoculating candidate monoclonal cell lines into immunodeficient animals to select non-tumorigenic cell lines; and viral susceptibility evaluation of the non-tumorigenic cell lines to select cell lines with predetermined susceptibility to a predetermined virus. This MDCK monoclonal cell line is non-tumorigenic. This invention addresses the risks of population heterogeneity and potential tumorigenicity in existing MDCK cell lines while ensuring viral production efficiency, providing an ideal cell platform for producing safer and quality-controlled viral vaccines.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD
CBLB endonuclease variants, compositions, and methods of use
To provide improved genome editing compositions and methods for editing the CBLB gene.SOLUTION: The disclosure further provides a genome edited cell for the prevention, treatment, or amelioration of at least one symptom of cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency. In various embodiments, the present disclosure contemplates, in part, a polypeptide comprising a homing endonuclease (HE) variant that cleaves a target site in the human CBLB gene.SELECTED DRAWING: Figure 1
Owner:REGENERON PHARMACEUTICALS INC
Donor repair templates multiplex genome editing
ActiveUS12559742B2Organic active ingredientsAntibody mimetics/scaffoldsMultiplexAutoimmune condition
The present disclosure provides improved multiplex genome editing compositions and methods. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
Owner:NOVO NORDISK AS
Engineered t cells
The present disclosure provides improved compositions for adoptive T cell therapy for treating, preventing, or ameliorating at least one symptom of cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency or conditions associated therewith.
Owner:GENE MEDICAL IMMUNOTHERAPY LLC +1
Compositions and methods for the treatment of immunodeficiency
The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and / or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
Owner:ADMA BIOMANUFACTURING LLC